Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients
Authors:
Open Access
- 15 May 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Nuclear Medicine
- Vol. 3
Abstract
Introduction: The optimal strategy for differentiated thyroid cancer (DTC) patients treated with radioiodine (RAI) following thyroidectomy remains controversial. Multi-centre clinical studies are essential to identify strategies to improve patient outcomes while minimising treatment-induced toxicity.Materials and Methods: The INSPIRE clinical trial (ClinicalTrials.gov Identifier: NCT04391244) aims to investigate patient-specific dosimetry for DTC patients and to determine the range of absorbed doses delivered to target and non-target tissues and their relationship with treatment outcome and toxicity.Results: We report here initial results of the first 30 patients enrolled onto the INSPIRE trial. A large range of absorbed doses are observed for both thyroid remnants and salivary glands, with median values of 4.8 Gy (Range 0.2 – 242 Gy) and 0.3 Gy (Range 0.1 to 1.7 Gy), respectively.Discussion: The preliminary study results are encouraging and could help to improve our understanding of absorbed doses to thyroid remnants and normal organs following RAI therapy. Such knowledge could potentially enable patient-specific treatment planning with improved clinical outcomes and quality-of-life of patients.Keywords
This publication has 50 references indexed in Scilit:
- Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid CancerNew England Journal of Medicine, 2012
- Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid CancerNew England Journal of Medicine, 2012
- Iodine or Not (IoN) for Low-risk Differentiated Thyroid Cancer: The Next UK National Cancer Research Network Randomised Trial following HiLoClinical Oncology, 2012
- Whole-Body Dosimetry for Individualized Treatment Planning of 131I-MIBG Radionuclide Therapy for NeuroblastomaJournal of Nuclear Medicine, 2009
- Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysisThyroid®, 2009
- MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of NomenclatureJournal of Nuclear Medicine, 2009
- Second Primary Malignancy Risk in Thyroid Cancer Survivors: A Systematic Review and Meta-AnalysisThyroid®, 2007
- Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancerNuclear Medicine Communications, 2006
- Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET ImagingClinical Positron Imaging, 1999
- Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid CancerNew England Journal of Medicine, 1983